Immunocore Holdings plc

NASDAQ:IMCR

Biotechnology

Healthcare
$27.51 +0.63%

+$0.18 today

Market cap
$1.42B
Beta
0.75
P/E (TTM)
-77.5
EPS (TTM)
-$0.37
52W Low $27.56High $40.72

Volume 0.30M

Average 0.40M

IMCR Income Before Tax

Profit after all operating and non-operating items but before income tax.

Immunocore Holdings plcNASDAQ: IMCR

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax growth accelerates

Q1 FY2026 income before tax of $13.27M rose 118.1% year over year, ahead of the +65.7% change in trailing-twelve-month income before tax.

Context

  • Income before tax amounted to 4.8% of revenue in FY2025, down 12.3 pp from a year earlier.
  • Income before tax grew in size in 1 of the last 3 fiscal years.
  • FY2025 was the smallest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +118.1% holds above the trailing-twelve-month pace of +65.7%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$13.27M+213.4% QoQ
Last fiscal yearDec 2025
-$14.21M+66.4% YoY
LTMMar 2026
-$7.82M+65.7% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+118.1%——
1 year+66.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

Mixed currencies · from the income statement

Latest · FY2025
(14.21M) USD
Year-over-year change
+66.4%

Income Before Tax vs competitors

How IMCR compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +65.7% is the 2nd highest of 11, against a peer median of -45.5%.
  • Income before tax amounts to 2.0% of revenue for IMCR, versus a peer median of 458.0%.
IMCR Competitors
Income Before Tax for IMCR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
CGENCompugen Ltd.LTM Mar 2026$34.88M USD+463.6%—48.0%
IMCRImmunocore Holdings plcLTM Mar 2026-$7.82M USD+65.7%—2.0%
IPHAInnate Pharma S.A.FY2025-€49.18M EUR+0.6%—1764.5%
IMMPImmutep LimitedFY2025-A$61.43M AUD-43.8%—1218.0%
MGNXMacroGenics, Inc.LTM Mar 2026-$71.03M USD-29.5%—45.2%
JANXJanux Therapeutics, Inc.LTM Mar 2026-$114.48M USD-47.3%—529.7%
XNCRXencor, Inc.LTM Jun 2026-$160.85M USD+10.3%—153.2%
IMTXImmatics N.V.LTM Mar 2026-€215.35M EUR-1111.0%—577.4%
RCUSArcus Biosciences, Inc.LTM Jun 2026-$452M USD-47.7%—386.3%
IBRXImmunityBio, Inc.LTM Sep 2026-$1.11B USD-218.3%—607.9%
BNTXBioNTech SELTM Jun 2026-€1.64B EUR-321.6%—61.9%
Peer median (excluding IMCR) —-45.5%—458.0%

Competitors are the stored peer set for IMCR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

Mixed currencies
Metric
FY2021
Dec 2021 · GBP
FY2022
Dec 2022 · GBP
FY2023
Dec 2023 · GBP
FY2024
Dec 2024 · USD
FY2025
Dec 2025 · USD
Revenue27.04M144.23M197.39M247.98M297.57M
Cost of Revenue05.29M820.63K5.54M6.21M
Gross Profit27.04M138.94M196.57M242.44M291.36M
Gross Margin100.0%96.3%99.6%97.8%97.9%
Research & Development74.31M84.31M129.42M177.44M204.47M
Selling, General & Admin82.15M0114.35M121.17M120.62M
Operating Expenses156.46M181.71M243.77M298.77M325.09M
Depreciation & Amortization5.63M4.41M3.24M3.36M2.43M
EBITDA(123.58M)(38.35M)(40.87M)(38.5M)387.18K
EBITDA Margin-457.0%-26.6%-20.7%-15.5%0.1%
Operating Income(129.42M)(42.77M)(47.2M)(56.28M)(33.74M)
Operating Margin-478.5%-29.7%-23.9%-22.7%-11.3%
Interest Income65K3.76M14.23M25.62M16.48M
Interest Expense5.57M5.41M4.08M18.84M12.17M
Other Income / Expenses(3.92M)8.95M(982.07K)14.01M19.53M
Income Before Tax(133.34M)(33.82M)(48.19M)(42.32M)(14.21M)
Pre-Tax Margin-493.0%-23.4%-24.4%-17.1%-4.8%
Income Tax Expense111.19K9.65M(4.43M)(1.48M)12.21M
Net Income(133.45M)(43.46M)(43.75M)(40.81M)(26.42M)
Net Margin-493.4%-30.1%-22.2%-16.5%-8.9%
EPS (Basic)(3.13)(0.95)(0.89)(1.02)(0.53)
EPS (Diluted)(3.00)(0.95)(0.89)(1.02)(0.53)
Weighted Avg Shares42.49M45.71M48.89M49.99M50.35M
Weighted Avg Shares (Diluted)43.86M45.71M48.89M49.99M50.35M

Immunocore Holdings plc

NASDAQ:IMCR

Intrinsic Alpha fair value

Locked

Current Price

$27.51

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.